UBS raised the firm’s price target on Insmed (INSM) to $140 from $133 and keeps a Buy rating on the shares. The approval of Brinsupri comes with an “in-line” label, while focus now turns to launch execution, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed downgraded to Equal Weight from Overweight at Morgan Stanley
- Insmed’s Brensocatib Approval Boosts Market Potential and Stock Valuation
- Insmed’s BRINSUPRI Approval and Strategic Pricing Justify Buy Rating and Increased Price Target
- Insmed price target raised to $140 from $130 at Wells Fargo
- Insmed price target raised to $138 from $120 at RBC Capital